ClinicalTrials.Veeva

Menu
W

Waikato Hospital | Cardiology Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Apremilast
Filgotinib
ABT-494
Etrolizumab
Ontamalimab
Vincristine
Guselkumab
cyclophosphamide
Gemcitabine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

56 of 225 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The purpose of this study is the evaluation of the performance, safety and efficacy of Hydra Aortic valve in real-world patients. Following initial i...

Active, not recruiting
Aortic Valve Stenosis
Device: Hydra TAVI

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potent...

Active, not recruiting
Coronary Disease
Coronary Stenosis
Procedure: FFR guided PCI
Device: Resolute Integrity Stent

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Vincristine Placebo
Drug: Polatuzumab vedotin Placebo

It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several f...

Active, not recruiting
Patient Preference
Leukemia, Myeloid, Acute
Drug: Oral decitabine/cedazuridine
Drug: Subcutaneous azacitidine

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting
Rheumatoid Arthritis
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus...

Active, not recruiting
Psoriatic Arthritis
Drug: Adalimumab
Drug: Placebo to Adalimumab

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling
Systemic Sclerosis With Lung Involvement
Idiopathic Pulmonary Fibrosis
Drug: Vixarelimab
Drug: Placebo

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Placebo Oral Tablet
Drug: Rucaparib

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversi...

Enrolling
Atrial Fibrillation
Drug: HBI-3000
Drug: Placebo

Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery...

Enrolling
Elevated IMR (>32)
STEMI
Drug: Tenecteplase (1/3 systemic weight based dose)
Other: Sterile water for injection (WFI)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

Trial sponsors

AbbVie logo
Pfizer logo
Roche logo
Gilead Sciences logo
Shire logo
T
Boehringer Ingelheim logo
G
Celgene logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems